PUB - Publikationen an der Universität Bielefeld

Deodhar, A., van der Heijde, D., Gensler, L., Xu, H., Gaffney, K., Dobashi, H., Maksymowych, W. P., et al. (2022). Bimekizumab Improves Signs and Symptoms, Including Inflammation, in Patients with Active Non-Radiographic Axial Spondyloarthritis: 24-Week Efficacy & Safety from a Phase 3, Multicenter, Randomized, Placebo Controlled Study. In American College of Rheumatology (Ed.), Arthritis & Rheumatology: Vol. 74. ABSTRACT SUPPLEMENT ACR Convergence 2022, November 10–14, 2022, Philadelphia, PA (pp. 1101-1105). Hoboken: Wiley. https://doi.org/10.1002/art.42355

Deodhar, A., van der Heijde, D., Gensler, L., Xu, H., Gaffney, K., Dobashi, H., Maksymowych, W. P., Rudwaleit, M., Magrey, M., Elewaut, D., et al. (2022). “Bimekizumab Improves Signs and Symptoms, Including Inflammation, in Patients with Active Non-Radiographic Axial Spondyloarthritis: 24-Week Efficacy & Safety from a Phase 3, Multicenter, Randomized, Placebo Controlled Study” in ABSTRACT SUPPLEMENT ACR Convergence 2022, November 10–14, 2022, Philadelphia, PA, American College of Rheumatology ed. Arthritis & Rheumatology, vol. 74, (Hoboken: Wiley), 1101-1105.

Deodhar, A., et al., 2022. Bimekizumab Improves Signs and Symptoms, Including Inflammation, in Patients with Active Non-Radiographic Axial Spondyloarthritis: 24-Week Efficacy & Safety from a Phase 3, Multicenter, Randomized, Placebo Controlled Study. In American College of Rheumatology, ed. ABSTRACT SUPPLEMENT ACR Convergence 2022, November 10–14, 2022, Philadelphia, PA. Arthritis & Rheumatology. no.74 Hoboken: Wiley, pp. 1101-1105.

A. Deodhar, et al., “Bimekizumab Improves Signs and Symptoms, Including Inflammation, in Patients with Active Non-Radiographic Axial Spondyloarthritis: 24-Week Efficacy & Safety from a Phase 3, Multicenter, Randomized, Placebo Controlled Study”, ABSTRACT SUPPLEMENT ACR Convergence 2022, November 10–14, 2022, Philadelphia, PA, American College of Rheumatology, ed., Arthritis & Rheumatology, vol. 74, Hoboken: Wiley, 2022, pp.1101-1105.

Deodhar, A., van der Heijde, D., Gensler, L., Xu, H., Gaffney, K., Dobashi, H., Maksymowych, W.P., Rudwaleit, M., Magrey, M., Elewaut, D., Oortgiesen, M., Fleurinck, C., de Peyrecave, N., Ellis, A., Vaux, T., Shepherd-Smith, J., Baraliakos, X.: Bimekizumab Improves Signs and Symptoms, Including Inflammation, in Patients with Active Non-Radiographic Axial Spondyloarthritis: 24-Week Efficacy & Safety from a Phase 3, Multicenter, Randomized, Placebo Controlled Study. In: American College of Rheumatology (ed.) ABSTRACT SUPPLEMENT ACR Convergence 2022, November 10–14, 2022, Philadelphia, PA. Arthritis & Rheumatology. 74, p. 1101-1105. Wiley, Hoboken (2022).

Deodhar, Atul, van der Heijde, Desiree, Gensler, Lianne, Xu, Huji, Gaffney, Karl, Dobashi, Hiroaki, Maksymowych, Walter P., Rudwaleit, Martin, Magrey, Marina, Elewaut, Dirk, Oortgiesen, Marga, Fleurinck, Carmen, de Peyrecave, Natasha, Ellis, Alicia, Vaux, Thomas, Shepherd-Smith, Julie, and Baraliakos, Xenofon. “Bimekizumab Improves Signs and Symptoms, Including Inflammation, in Patients with Active Non-Radiographic Axial Spondyloarthritis: 24-Week Efficacy & Safety from a Phase 3, Multicenter, Randomized, Placebo Controlled Study”. ABSTRACT SUPPLEMENT ACR Convergence 2022, November 10–14, 2022, Philadelphia, PA. Ed. American College of Rheumatology. Hoboken: Wiley, 2022.Vol. 74. Arthritis & Rheumatology. 1101-1105.